DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This research trial studies deoxyribonucleic acid (DNA) samples from younger patients with germ cell tumor and their parents or siblings. Studying samples of tumor tissue and saliva from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
| Condition | Intervention |
|---|---|
|
Childhood Malignant Ovarian Germ Cell Tumor Childhood Malignant Testicular Germ Cell Tumor Ovarian Choriocarcinoma Ovarian Embryonal Carcinoma Ovarian Mixed Germ Cell Tumor Ovarian Teratoma Ovarian Yolk Sac Tumor Testicular Choriocarcinoma Testicular Embryonal Carcinoma Testicular Seminoma Testicular Teratoma Testicular Yolk Sac Tumor |
Other: laboratory biomarker analysis Other: questionnaire administration |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
| Official Title: | Molecular Epidemiology of Pediatric Germ Cell Tumors |
- Pediatric GCT associated with genetic susceptibility [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]Will be modeled using a Poisson regression. A likelihood ratio test determines the statistical significance.
- List of genes that distinguish between the three most common histologic subtypes of pediatric GCT: yolk sac tumor, teratoma, and germinoma [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]A permutation based Chi-Square test for categorical covariates or a permutation based Kruskal-Wallis test (continuous risk factors) will be used.
- Validation of array results by pyrosequencing [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]A standard case-only approach evaluating differences in methylation by histology, age and gender will be done using chi-square and ANOVA.
Biospecimen Retention: Samples With DNA
Saliva and tissue
| Estimated Enrollment: | 932 |
| Study Start Date: | November 2011 |
| Estimated Primary Completion Date: | November 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Correlative studies
Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
|
Other: laboratory biomarker analysis
Correlative studies
Other: questionnaire administration
Ancillary studies
|
Detailed Description:
OBJECTIVES:
I. To evaluate associations between genetic variation and pediatric germ cell tumor (GCT) using a case-parent triad design to identify variants in four genes, KITLG, SPRY4, BAK1, and DMRT1, associated with pediatric GCT.
II. To evaluate associations between genetic variation and pediatric GCT using a case-parent triad design to include targeted genotyping of single nucleotide polymorphisms (SNPs) in selected key pathways essential for normal in utero germ cell development, specifically genes involved in survival of germ cells during migration, apoptosis, and cell cycle control.
III. To explore inter- and intratumoral heterogeneity in DNA methylation by tumor histology.
OUTLINE: This is a multicenter study.
Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific polymerasechain reaction (PCR) (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
Eligibility| Ages Eligible for Study: | up to 19 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Primary care clinic
Inclusion Criteria:
- The patient is enrolled on COG-ACCRN07
- The patient has a primary diagnosis of germ cell tumor (GCT) including germinoma (ICCC 9060-9065) teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071),choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105) in all sites including the brain and central nervous system and registered with Children's Oncology Group (COG) by a North American member institution
- The patient must be diagnosed with a germ cell tumor between July 1, 2008 and December 31, 2015
- The patient must be < 20 years of age at the time of diagnosis
The patient must have at least one biological parent alive and willing to participate
- In the event that one case parent cannot contribute DNA, a case sibling, defined as the biological brother or sister of the study subject, may donate instead
- All questionnaire respondents must understand English or Spanish
- Concomitant treatment on a therapeutic trial is not required
Contacts and Locations| United States, California | |
| Children's Oncology Group | Recruiting |
| Arcadia, California, United States, 91006-3776 | |
| Contact: Jenny Poynter 612-625-4232 poynt006@umn.edu | |
| Principal Investigator: Jenny Poynter | |
| Principal Investigator: | Jenny Poynter | Children's Oncology Group |
More Information
No publications provided
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT01434355 History of Changes |
| Other Study ID Numbers: | AEPI10N1, NCI-2011-03464, CDR0000711070, COG-AEPI10N1 |
| Study First Received: | September 13, 2011 |
| Last Updated: | June 10, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Carcinoma Choriocarcinoma Endodermal Sinus Tumor Seminoma Teratoma Testicular Neoplasms Neoplasms, Germ Cell and Embryonal Carcinoma, Embryonal Germinoma Ovarian Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Trophoblastic Neoplasms Gestational Trophoblastic Neoplasms |
Adenocarcinoma Pregnancy Complications, Neoplastic Pregnancy Complications Mesonephroma Endocrine Gland Neoplasms Neoplasms by Site Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Endocrine System Diseases Testicular Diseases Gonadal Disorders Ovarian Diseases Adnexal Diseases Genital Diseases, Female |
ClinicalTrials.gov processed this record on June 18, 2013